A new method of monitoring osteomyelitis

Springer, Ingo N.; Wiltfang, Jens; Dunsche, Anton; G, Lier; Bartsch, M; Warnke, Patrick H.; Barth, Ernst; Terheyden, Hendrik; Russo, Paul; Czech, Norbert; Açil, Yahya

doi:10.1016/j.ijom.2007.01.001

Cited by 15 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Philopov et al and Southwood et al found increased turnover markers in experimentally induced osteomyelitis in animals [18–19]. Springer et al found elevated urine bone resorption marker levels of lysylpyridnoline and hydroxylysylpyridinoline in human patients with acute mandibular osteomyelitis [20]. Levels decreased in patients with a good response to treatment but remained elevated in patients with ongoing disease.…”

Section: Introductionmentioning

confidence: 99%

Diabetic foot osteomyelitis: Bone markers and treatment outcomes

Nyazee

Finney

Sarikonda

et al. 2012

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Aims Novel bone turnover markers could help with the diagnosis and monitoring of osteomyelitis patients. We compared levels of two bone turnover markers, serum amino-terminal telopeptides (NTx) and bone alkaline phosphatase (BAP), in diabetic patients with and without osteomyelitis. Methods Matched case-control study was conducted with diabetic patients with and without osteomyelitis. Cases not undergoing immediate amputation were followed with repeat measurements after osteomyelitis treatment and for outcome determination. Results Analysis included 54 subjects, 27 cases and 27 controls. Median BAP levels were similar between cases and controls at enrollment (p=.55) as were median NTx levels (p=.43). Cases with follow-up data (n = 18) had similar bone marker levels at enrollment and 6 weeks. No significant differences in BAP or NTx levels at enrollment or follow-up were seen between cases with poor versus favorable outcomes. Conclusions No differences in NTx or BAP levels were seen between cases and controls. Cases with follow-up data had similar levels at enrollment and 6 weeks. Lack of difference may be due to small sample size, small areas of bone involved in foot osteomyelitis, or limitations of these specific markers. More research is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Diabetic foot osteomyelitis: Bone markers and treatment outcomes

Nyazee

Finney

Sarikonda

et al. 2012

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…[ 29 30 ] In spite of these, our results are consistent with others findings of diagnostic usefulness of BTM in bone infection. [ 11 12 ]…”

Section: Discussionmentioning

confidence: 99%

“…Bone-specific inflammatory markers have been reported in animal studies and recently in humans to be a possible diagnostic marker for DFO. [ 8 9 10 11 12 13 ] Thus, use of bone turnover markers (BTMs) appears appealing in diagnosing bone infection as the diabetic foot ulcer acts as a portal of entry for microbial invasion into bone. Importantly, osteomyelitis is recognized as a state of both enhanced bone resorption and formation.…”

Section: Introductionmentioning

confidence: 99%

Serum procollagen type 1 N propeptide: A novel diagnostic test for diabetic foot osteomyelitis – A case–control study

2018

View full text Add to dashboard Cite

Background:The objective of the study was to determine whether serum levels of procollagen type 1 N propeptide (P1NP), a bone formation turnover marker, differs between diabetic foot ulcer with osteomyelitis (DFO) and diabetic foot ulcers without osteomyelitis serving as controls. It was also aimed to assess the usefulness of P1NP in diagnosing DFO compared to other common inflammatory markers.Materials and Methods:A case–control study was designed comparing the aforementioned groups. Patients were classified as osteomyelitis and controls based on the International Working Group diagnostic criteria. Serum P1NP and three other inflammatory markers, namely, C-reactive protein (CRP), white blood cells (WBC), and platelets were analyzed on patients with DFO and controls.Results:The mean serum P1NP levels were significantly higher in the DFO group (n: 16), 10.5 ± 5.2 (ng/ml), than the control group (n: 11) 3.1 ± 2.8 (ng/ml), P = 0.001. P1NP showed the highest sensitivity/specificity 86.7%/80% compared to 70.6%/80%, 56.2%/45.4%, and 50%/37% for CRP, WBC and platelets, respectively. Receiver operator characteristic curves showed the best value of area under the curve of 0.9 for P1NP compared to 0.85, 0.54, and 0.46 for CRP, WBC, and platelets.Conclusion:We found marked elevation of serum P1NP in diabetic foot ulcer with bone infection with potential value in using it to diagnose DFO.

show abstract

“…LP is found in Type I collagen of bone and dentin. HP and LP were used in other studies as biomarkers for rheumatoid arthritis, osteomyelitis, osteoarthritis, , osteoporosis, , and oral cancer . DESs, HP, and LP can be excreted as free pyridinium analogues (free form) or covalently attached to peptides (bounded form).…”

mentioning

confidence: 99%

“…DESs, HP, and LP can be excreted as free pyridinium analogues (free form) or covalently attached to peptides (bounded form). To identify all of these cross-linkers, (Total = free + bounded forms) the samples are digested in acid to release the bounded form. ,,,,,− Results from other research groups , suggest that the free cross-linkers and the peptides-bounded cross-linkers excreted in urine are generated by different degradation pathways. For example, Ma et al measured an increased urinary excretion of free DESs for COPD patients compared to controls while total DESs remained unaffected.…”

mentioning

confidence: 99%

NanoLC-MS/MS Analyses of Urinary Desmosine, Hydroxylysylpyridinoline and Lysylpyridinoline as Biomarkers for Chronic Graft-versus-Host Disease

et al. 2009

View full text Add to dashboard Cite

Chronic graft-versus-host disease (cGVHD) is a common and potentially lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). cGVHD as well as the transplant procedure itself (chemotherapy with or without radiotherapy) can lead to the degradation of connective tissue components such as elastin and collagen. The catabolism of these structural proteins releases desmosine (DES), lysylpyridinoline (LP), hydroxylysylpyridonoline (HP), and related pyridinium-based cross-linkers analogues that could represent potential biomarkers for cGVHD. This study reports the development of a sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous analysis of N-propyl derivatives of DES, HP, and LP. The concentrations of free and total forms of urinary DES, HP, and LP were determined using synthetic deuterated internal standards. This method enabled accurate quantitation of these pyridinium-based cross-linkers from as little as 100 microL of urine with detection limits of 0.03-0.10 ng/mL. These compounds were analyzed in urine samples from three groups of patients: (1) Healthy volunteers, (2) Autologous HSCT recipients (who cannot develop cGVHD), and (3) Allogeneic HSCT recipients at onset of cGHVD. These analyses revealed that the urinary concentrations of DES, HP, and LP in the autologous recipients were greater or equal to the cGVHD group although both groups showed marked increase in the levels of these compounds compared to healthy individuals. These results suggest that the chemotherapy treatment has significant effects on the turnover of elastin and collagen, and that these biomarkers could be effective during prospective analyses to determine the onset of cGVHD.

show abstract

A new method of monitoring osteomyelitis

Cited by 15 publications

References 38 publications

Diabetic foot osteomyelitis: Bone markers and treatment outcomes

Diabetic foot osteomyelitis: Bone markers and treatment outcomes

Serum procollagen type 1 N propeptide: A novel diagnostic test for diabetic foot osteomyelitis – A case–control study

NanoLC-MS/MS Analyses of Urinary Desmosine, Hydroxylysylpyridinoline and Lysylpyridinoline as Biomarkers for Chronic Graft-versus-Host Disease

Contact Info

Product

Resources

About